Abstract: The present disclosure generally relates to a method for reducing the toxicity of polymyxins as a therapeutic agent comprising the step of coadministration of an aminoglycoside; a method for improving the aerosolization of an aminoglycoside comprising the step of combination formulation with a polymyxin; and a process for manufacturing a dry powder composition comprising a polymyxin and aminoglycoside. Pharmaceutical compositions and methods of treatment for lung infections are within the scope of this invention.

Abstract: The present disclosure generally relates to a method for reducing the toxicity of inhaled polymyxins as a therapeutic agent comprising the step of co-administration of an aminoglycoside; a method for improving the aerosolization of an aminoglycoside comprising the step of combination formulation with a polymyxin; and a process for manufacturing a dry powder composition comprising a polymyxin and aminoglycoside. Pharmaceutical compositions and methods of treatment for lung infections are within the scope of this invention.

Abstract: The present invention relates to a solid oxide fuel cell especially protonic ceramic fuel cell which can operate at intermediate temperature and fuel cell thereof. The composition comprising a formula BaCe0.7Zr0.25-xYxZn0.05O3-? or BaCe0.7Zr0.1Y0.2-xPrxO3-?, wherein x=0.05, 0.1, 0.15, 0.2 or 0.25 to vary Zr and Y percentage at the B-site, and Ba=100%, Ce=70%; and Zn=5%.

Abstract: A passive radiative thermostat (PRT) is provided. The PRT comprises a phase-change part comprising a thermochromic phase change material; and a wavelength-selector part designed to create electromagnetic resonances in a wavelength range. The wavelength range may include the visible range, the near-infrared range, or the mid-infrared range. The wavelength-selector part may include an electromagnetic cavity resonator or an electromagnetic plasmonic resonator. Further, the phase-change part may include a thermochromic film; and the wavelength-selector part may include a dielectric spacer.

Abstract: The present invention relates to a solid oxide fuel cell especially protonic ceramic fuel cell which can operate at intermediate temperature and fuel cell thereof. The composition comprising a formula BaCe0.7Zr0.25-xYxZn0.05O3-? or BaCe0.7Zr0.1Y0.2-xPrxO3-?, wherein x=0.05, 0.1, 0.15, 0.2 or 0.25 to vary Zr and Y percentage at the B-site, and Ba=100%, Ce=70%; and Zn=5%.

Abstract: A passive radiative thermostat (PRT) is provided. The PRT comprises a phase-change part comprising a thermochromic phase change material; and a wavelength-selector part designed to create electromagnetic resonances in a wavelength range. The wavelength range may include the visible range, the near-infrared range, or the mid-infrared range. The wavelength-selector part may include an electromagnetic cavity resonator or an electromagnetic plasmonic resonator. Further, the phase-change part may include a thermochromic film; and the wavelength-selector part may include a dielectric spacer.

Abstract: The present invention relates to an electrolyte composition and method of making thereof. The proton conducting electrolyte composition i.e. Sr1-xBaxCe0.5Zr0.35Y0.1Sm0.05O3-?, comprises combination of doped BaCeO3 and BaZrO3 by their doping in Sr, Y, and Sm, wherein x=0 to 0.99, and ?=0 to 0.1. The proton conducting electrolyte is used as at least one component, among others, of Solid Oxide Fuel Cells such Solid Oxide Fuel Cell (SOFC) can easily be operated at intermediate temperature about 600° C. thereby making the SOFC cost effective and reliable and showing highest power density.

Abstract: The present invention provides processes for the preparation of baricitinib of Formula I and an intermediate of Formula V. The present invention also provides the use of the intermediate of Formula V for the preparation of baricitinib.

Abstract: The present invention provides processes for the preparation of baricitinib of Formula I and an intermediate of Formula V. The present invention also provides the use of the intermediate of Formula V for the preparation of baricitinib.

Abstract: The present invention relates to an electrolyte composition and method of making thereof. The proton conducting electrolyte composition i.e. Sr1-xBaxCe0.5Zr0.35Y0.1Sm0.05O3-?, comprises combination of doped BaCeO3 and BaZrO3 by their doping in Sr, Y, and Sm, wherein x=0 to 0.99, and ?=0 to 0.1. The proton conducting electrolyte is used as at least one component, among others, of Solid Oxide Fuel Cells such Solid Oxide Fuel Cell (SOFC) can easily be operated at intermediate temperature about 600° C. thereby making the SOFC cost effective and reliable and showing highest power density.

Abstract: The present invention provides a process for the preparation of baricitinib and an intermediate thereof. The present invention provides a convenient, economical, and industrially advantageous two-step process for the preparation of [4-(IH-pyrazol-4-yl)-7Hpyrrolo[2,3-d] pyrimidin-7-yl]methyl pivalate of Formula (II). The process of the present invention involves the use of an alkali or alkaline earth metal hydroxide, carbonate, or bicarbonate as a base for reacting 4-chloro-7H-pyrrolo[2,3-d]pyrimidine of Formula (III) with chloromethyl pivalate of Formula (IV), and the use of an unprotected pyrazole borolane of Formula (VIII) for the conversion of (4-chloro-7H-pyrrolo[2,3-d] pyrimidin-7-yl)methyl 2,2-dimethylpropanoate of Formula V into [4-(1H-pyrazol-4-yl)-7Hpyrrolo[2,3-d]pyrimidin-7-yl]methyl pivalate of Formula (II). The process of the present invention provides [4-(1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]methyl pivalate of Formula (I) in high yield.

Abstract: The present invention provides a process for the preparation of baricitinib and an intermediate thereof. The present invention provides a convenient, economical, and industrially advantageous two-step process for the preparation of [4-(IH-pyrazol-4-yl)-7Hpyrrolo[2,3-d] pyrimidin-7-yl]methyl pivalate of Formula (II). The process of the present invention involves the use of an alkali or alkaline earth metal hydroxide, carbonate, or bicarbonate as a base for reacting 4-chloro-7H-pyrrolo[2,3-d]pyrimidine of Formula (III) with chloromethyl pivalate of Formula (IV), and the use of an unprotected pyrazole borolane of Formula (VIII) for the conversion of (4-chloro-7H-pyrrolo[2,3-d] pynmidin-7-yl)methyl 2,2-dimethylpropanoate of Formula V into [4-(1H-pyrazol-4-yl)-7Hpyrrolo[2,3-d]pyrimidin-7-yl]methyl pivalate of Formula (II). The process of the present invention provides [4-(1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]methyl pivalate of Formula (I) in high yield.

Abstract: The present invention relates to a process for the preparation of azilsartan medoxomil or pharmaceutically acceptable salts thereof.

Abstract: A pharmaceutical composition is provided for the oral administration of an NSAlD and a prostaglandin. The composition is a solid dosage form wherein the NSAID is enterically coated and the prostaglandin is present along with an effective stabilizing amount of a prostaglandin stabilizing agent such as hydroxypropyl methylcellulose or polyvinylpyrrolidone. Exemplary dosage forms are bilayer tablets in which the prostaglandin is misoprostol and the NSAID is diclofenac, piroxicam, or a pharmaceutically acceptable salt thereof. Methods for using the composition to treat NSAID-responsive conditions, disorders and diseases are provided as well.

Abstract: A pharmaceutical composition is provided for the oral administration of an NSAID and a prostaglandin. The composition is a solid dosage form wherein the NSAID is enterically coated and the prostaglandin is present along with an effective stabilizing amount of a prostaglandin stabilizing agent such as hydroxypropyl methylcellulose or polyvinylpyrrolidone. Exemplary dosage forms are bilayer tablets in which the prostaglandin is misoprostol and the NSAID is diclofenac, piroxicam, or a pharmaceutically acceptable salt thereof. Methods for using the composition to treat NSAID-responsive conditions, disorders and diseases are provided as well.